Shamburg News · 8-K filed Oct 26, 2026, 4:44 PM EDT
Longeveron Reports Updated ELPIS II Results; MACE Endpoint Reaches Statistical Significance
LGVN · Longeveron Inc.
- Other event
- Reg FD disclosure
- Materiality: medium
On October 26, 2026, Longeveron Inc. announced updated results from its Phase 2b ELPIS II trial of laromestrocel in 40 infants with hypoplastic left heart syndrome, disclosed in Item 8.01 and Exhibit 99.1. The trial did not meet its primary RVEF endpoint at Month 12, but the pre-specified secondary endpoint MACE showed 8 events in the standard of care arm versus 1 in the laromestrocel arm (P=0.043). The Company intends to request a meeting with the FDA to review the results and determine potential next steps for the HLHS program.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001213900-26-112508.
Written from the filing by Shamburg Markets. Figures are as reported by the company.